PeptiDream Inc. (TYO:4587)
1,481.00
+70.50 (5.00%)
At close: Mar 6, 2026
PeptiDream Employees
PeptiDream had 751 employees as of December 31, 2025. The number of employees increased by 130 or 20.93% compared to the previous year.
Employees
751
Change
130
Growth
20.93%
Revenue / Employee
24.66M JPY
Profits / Employee
-4.99M JPY
Market Cap
191.37B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 751 | 130 | 20.93% |
| Sep 30, 2025 | 756 | 21 | 2.86% |
| Jun 30, 2025 | 757 | 12 | 1.61% |
| Mar 31, 2025 | 736 | 36 | 5.14% |
| Dec 31, 2024 | 621 | 18 | 2.99% |
| Sep 30, 2024 | 735 | 31 | 4.40% |
| Jun 30, 2024 | 745 | 53 | 7.66% |
| Mar 31, 2024 | 700 | 30 | 4.48% |
| Dec 31, 2023 | 603 | 34 | 5.98% |
| Sep 30, 2023 | 704 | 34 | 5.07% |
| Jun 30, 2023 | 692 | 53 | 8.29% |
| Mar 31, 2023 | 670 | 31 | 4.85% |
| Dec 31, 2022 | 569 | 392 | 221.47% |
| Sep 30, 2022 | 670 | 501 | 296.45% |
| Mar 31, 2022 | 639 | 481 | 304.43% |
| Dec 31, 2021 | 177 | 27 | 18.00% |
| Sep 30, 2021 | 169 | 23 | 15.75% |
| Jun 30, 2021 | 175 | 38 | 27.74% |
| Mar 31, 2021 | 158 | 34 | 27.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takara Bio | 1,779 |
| GNI Group | 867 |
| Nxera Pharma | 382 |
| Japan Tissue Engineering | 204 |
| Healios K.K. | 65 |
| RaQualia Pharma | 64 |
| Cuorips | 56 |
| AnGes | 55 |
PeptiDream News
- 4 weeks ago - Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan - GlobeNewsWire
- 2 months ago - PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis - Business Wire